Q2 2025 Earnings Call Transcript January 30, 2025 Cardinal Health, Inc. beats earnings expectations. Reported EPS is $1.93, ...

Bank of America Securities analyst Allen Lutz maintained a Buy rating on Cardinal Health (CAH – Research Report) today. The company’s shares ...

Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday.Invest with ...

Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.

Valiquette also increased his earnings per share (EPS) estimates for Cardinal Health (NYSE:CAH), raising the fiscal year 2025 forecast from $7.90 to $7.95 and the fiscal year 2026 projection from $8 ...

Cardinal Health Inc. hit a new 52-week high, surpassing its previous peak of $129.68, which the company achieved on January ...

Dublin City Schools is officially withdrawing from an agreement with Cardinal Health to purchase a vacant office building, Superintendent John Marschhausen told board members at a meeting Monday ...

Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals ...